touchDERMATOLOGY touchDERMATOLOGY
Prurigo nodularis
Watch Time: 3 mins

OLYMPIA 2: nemolizumab improves prurigo nodularis-associated pain and patient reported outcomes: Adam Reich, EADV 2023

Copy Link
Published Online: Oct 16th 2023

OLYMPIA 2 (NCT04501679) was a phase 3, multicentre, double-blind study that investigated the IL-31 inhibitor nemolizumab for the treatment of prurigo nodularis in adults.

touchDERMATOLOGY were delighted to speak with Prof. Adam Reich (University of Medicine, Wroclaw, Poland) around his analysis of OLYMPIA 2, looking at improvements in pain and patient reported outcomes.

This information is provided solely by Touch Medical Media and is independent of any sponsorship or affiliation with the European Academy of Dermatology & Venereology (EADV).

The abstract ‘Nemolizumab modulates prurigo nodularis-associated skin pain and markedly improves patient reported outcomes in patients with moderate-to-severe prurigo nodularis in a phase 3 study (OLYMPIA 2).’ (Abstract N°: 4147) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress.

Questions

  1. What is the mechanism of action and rationale for investigating nemolizumab in prurigo nodularis? (0:18)
  2. Could you describe the aims and design of the phase 3 OLYMPIA 2 study, and how well the key endpoints were met? (0:50)
  3. What additional outcomes were investigated in your analysis of OLYMPIA 2 and how well were they met? (1:29)
  4. What will be the next steps in the clinical development of  nemolizumab? (2:05)

Disclosures: Adam Reich discloses receiving grant/research support from Abbvie, Anaptys, BMS, Dice, Eli Lilly, Galderma, Incyte, Jannsen, Medac, Novartis, Pfizer, Regeneron, Trevi Therapeutics, and UCB; serving on advisory boards for Abbvie, Galderma, Leo Pharma, Sanofi, Novartis, and Eli Lilly.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.

Filmed in coverage of the EADV Annual Meeting.

Click here for more content on prurigo nodularis & for further EADV 2023 highlights visit here.

Share this Video
Related Videos In Prurigo nodularis
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72